All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-03-30T09:24:48.000Z

What are the advantages of CAR T-cells derived from pluripotent stem cells?

By Marcia Rato, Alice Hyde
Featured
Maria Themeli
Mar 30, 2021
Share:

Bookmark this article

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Maria Themeli, Amsterdam UMC, Amsterdam, NL. We asked, What are the advantages of CAR T-cells derived from pluripotent stem cells?

What are the advantages of CAR T-cells derived from pluripotent stem cells?

In this video, the background to the use of induced pluripotent stem cells (iPCs) is discussed along with the role of genome editing with respect to the production of these CAR T-cells.

More about...
CAR therapyCAR-T 2021CAR-T Meetings

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
19 votes - 11 days left ...

Related articles

Add bookmark

CAR-T versus bispecific antibodies and BiTEs in multiple myeloma

Chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (bsAbs)/bispecific T-cell engagers (BiTEs), even though they present structural similarities, differ in their mode of...

Apr 12, 2021
Add bookmark

CAR-T versus bispecific antibodies and BiTEs in multiple myeloma

Chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (bsAbs)/bispecific T-cell engagers (BiTEs), even though they...

Apr 12, 2021
Add bookmark

The impact of COVID-19 on the management of patients with multiple myeloma

An article, by Elena Zamagni, Paola Tacchetti, and Michele Cavo, discussing the impact of COVID-19 on the management of patients with multiple myeloma. SARS-CoV-2.

Mar 24, 2020
Add bookmark

The impact of COVID-19 on the management of patients with multiple myeloma

An article, by Elena Zamagni, Paola Tacchetti, and Michele Cavo, discussing the impact of COVID-19 on the management of...

Mar 24, 2020

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox